Overview

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Status:
Completed

Trial end date:
2020-03-16

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the safety and tolerability of MK-7625A (ceftolozane/tazobactam) plus metronidazole, compared with that of meropenem in pediatric participants with cIAI.

Phase:

Phase 2

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Treatments:

Ceftolozane
Ceftolozane, tazobactam drug combination
Cephalosporins
Meropenem
Metronidazole
Penicillanic Acid
Tazobactam
Thienamycins